Key result
Peripartum cardiomyopathy is a rare idiopathic form of heart failure affecting women during or after pregnancy, with an estimated incidence of 18 to 333 per 100,000 births.
Peripartum cardiomyopathy is a rare, idiopathic heart failure occurring peripartum, managed with pregnancy-adjusted standard heart failure therapies and potentially prolactin blockade.
Answers are grounded in this paper and cite their sources.
Prompts inclusion in peripartum HF differentials; leaves open optimal pregnancy-adjusted therapies.
Peripartum cardiomyopathy (PPCM) is a relatively rare idiopathic form of heart failure that affects women during the last months of pregnancy or the first months after delivery. The aetiology and pathophysiological mechanisms of this disease are poorly characterised and incompletely understood. Diagnosis remains a challenge, as PPCM symptoms vary and may mimic those commonly experienced by women during pregnancy and postpartum due to normal physiological changes that occur during this period. The clinical course varies between complete recovery to rapid progression to end stage heart failure and even death. Standard heart failure treatment, with adjustments for women who are pregnant or lactating, is the treatment of choice. Disease specific therapeutic strategies, including prolactin blockade, show promise. National and international registries and collaborative research efforts are warranted to characterise this disease better and to develop novel treatments that can improve outcomes. Heart failure during pregnancy has been recognised since the mid 19th century, but it was not until 1971 that Demakis and colleagues proposed diagnostic criteria for PPCM.w1 These diagnostic criteria have subsequently been revised by several groups1 2 w2 (table 1). View this table: Table 1 Definition of peripartum cardiomyopathy The common elements in all of the proposed criteria are that PPCM is a relatively rare idiopathic form of heart failure with left ventricular (LV) systolic dysfunction that occurs during the peripartum period. The true incidence of PPCM is unknown, as clinical presentation varies and no systematic epidemiological studies have been conducted. Current estimates, ranging between 18 per 100 000 and 333 per 100 000 births, are primarily based on case series from single centres (figure 1). Figure 1 The reported incidence of peripartum cardiomyopathy (PPCM) in the USA varies considerably, while the reported incidences in several African and Asian countries are similar.
No takes yet. Share an insight, caveat, or question.
Blauwet et al. (2011) conducted a review in Peripartum cardiomyopathy. Peripartum cardiomyopathy is a rare idiopathic form of heart failure affecting women during or after pregnancy, with an estimated incidence of 18 to 333 per 100,000 births.
Synapse has enriched 10 related papers. Consider them for comparative context: